For this reason, the European LeukemiaNet recommendations on BCR‐ABL1 mutation testing in CML underlined the importance of using sequencing approaches rather than mutation‐specific assays, enabling screening for a limited number of mutations only. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.